Bellerophon Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Bellerophon Therapeutics

31/03/2022 22:25

* Bellerophon Therapeutics Inc  BLPH.OQ  reported a
quarterly
adjusted loss of 45 cents​​ per share for the quarter ended in
December. The mean expectation of two analysts for the quarter
was for a loss of 60 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * The mean earnings estimate of analysts had risen by
about 6.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Bellerophon Therapeutics Inc shares had fallen by 24.5%
this
quarter.
    * Wall Street's median 12-month price target for Bellerophon
Therapeutics Inc is $26.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 31 at 09:24 p.m.  ​All
figures in US dollars unless otherwise stated